The Weight Loss Revolution Comes to India, As Semaglutide Patent Expires, Generic Drugs Promise Affordability and Access
With Prices Expected to Drop by 60 Per Cent, a New Era Begins for Diabetes and Obesity Treatment—But Experts Warn Against Misuse
Later this month, a quiet revolution will unfold in India’s pharmaceutical market. When the patent on semaglutide expires, nearly 50 brands are expected to enter the market, offering generic versions of the blockbuster drug that has transformed diabetes and obesity treatment worldwide. Not only will this expand access to this new class of medicines, but prices are also likely to drop by at least a third—and potentially much more—according to market experts.
The new products will be launched at a third to a fifth of the cost of the innovator drug and are already being called “generic Ozempic” and “generic Wegovy.” With pharma majors such as Dr Reddy’s, Zydus, Sun Pharmaceuticals, Cipla, and Lupin in the fray, the monthly cost of the once-a-week semaglutide injectable is likely to come down to between Rs 3,000 and Rs 4,000. The current price of Ozempic ranges between Rs 8,800 and Rs 11,175 per month, depending on dosage, while Wegovy costs between Rs 10,850 and Rs 16,400.
This is not just a story about lower prices. It is a story about access, about the democratisation of cutting-edge medical treatment, about millions of Indians who will now be able to afford therapies that were previously out of reach. And it is a story about the pharmaceutical industry’s response to patent expiry—the moment when innovation becomes generic, when monopoly gives way to competition, when the benefits of research finally reach the masses.
The Science of Semaglutide
Semaglutide has been a hot-seller because it mimics the GLP-1 hormone, which is released in the gut after eating, to stimulate insulin production, lower blood sugar, slow digestion, and reduce appetite. It was first approved for the treatment of Type-2 diabetes by the US Food and Drug Administration (FDA) in 2017. However, it soon gained popularity for its off-label use as a weight loss agent. A higher-dose version of the medicine was finally approved for weight loss by the FDA in 2021.
Danish pharma major Novo Nordisk, the primary patent holder of semaglutide, sold Ozempic primarily for Type 2 diabetes, but its appetite-suppressing ability made it highly effective for weight management. Its Wegovy is specifically tailored to control chronic obesity. Both were launched in India last year, before the patent expired.
The mechanism is elegant and effective. By mimicking a natural hormone, semaglutide tells the body that it is full, reducing appetite and caloric intake. For people with Type 2 diabetes, it helps control blood sugar. For those struggling with obesity, it offers a pharmacological tool to support weight loss. The combination of benefits has made it one of the most sought-after drugs in pharmaceutical history.
The Market Transformation
With the semaglutide patent expiring, the weight loss drug boom in the West is now expected to hit India more strongly with generics, which will be the same as brand-name drugs in dosage, safety, strength, quality, and performance, but usually cost significantly less as they do not have to repeat costly clinical trials.
While nearly 50 brands will be launched, only three or four of the bigger brands are likely to grab a share of the pie. “Other brands from smaller companies, which only a few doctors prescribe, are likely to fade away. This is what we have seen with other diabetes drugs that have gone off patent,” said Sheetal Sapale, vice president (commercial) at Pharmarack.
This pattern is familiar in the pharmaceutical industry. When a patent expires, a flood of generic manufacturers enter the market, prices plummet, and competition intensifies. Over time, the market consolidates around a few trusted brands, and the smaller players fade away. Patients benefit from lower prices, while the industry adapts to the new competitive landscape.
The Innovator Response
Despite the competition, the two market leaders—Novo Nordisk and Eli Lilly—are unlikely to change their current price points. “We are driven by patients, not patents. Patent expiry is a natural part of the pharmaceutical product life cycle and we are well positioned to navigate this evolving landscape,” said Vikrant Shrotriya, managing director of Novo Nordisk India.
Shrotriya emphasised the value proposition of the innovator products: “Semaglutide carries a strong clinical evidence base of proven safety and efficacy with over 50 robust clinical trials across Type 2 diabetes, obesity, heart, liver and kidney disease. This is complemented by 49 million patient-years of exposure, extensive real-world evidence, world-class r-DNA manufacturing process, state-of-the-art device and delivery system and high safety standards.”
This is not just marketing talk. Innovator drugs come with extensive clinical data, established safety profiles, and sophisticated delivery systems. For patients who can afford them, the premium may be worth paying. But for the millions who cannot, generics offer a lifeline.
The Market Dynamics
While the newer drugs are likely to eat into some of Mounjaro’s market share, the change is not likely to happen immediately. “The people who are already on Mounjaro or Wegovy can afford these drugs. They are unlikely to shift to the generic versions immediately despite the lower costs. This is because they value the premium quality of the innovator products and a shift to a new product may lead to the initial side effects again,” explained Sapale.
The lower-cost generic versions are likely to lead to a two-to-threefold surge in the number of people using them, including those who kept away from the drug because of its prices. This is the real story of patent expiry: not substitution but expansion. The market grows because more people can participate.
“Generics are likely to capture a bigger volume share as GLP-1 therapy becomes more affordable, accessible and awareness about management of diabetes and obesity goes up… This is expected to enable more patients to initiate therapy while also supporting continuity of treatment,” said Dr Vikas Gupta, Chief Executive Officer of Alkem Laboratories. The company is set to launch its generic version of semaglutide on the first day of patent expiry.
Innovation in Delivery
Several drug manufacturers will be launching multiple brands. For instance, Zydus Lifesciences plans to launch Semaglyn, Mashema, and Alterme. Companies are also looking at innovations to capture the market. Zydus will launch semaglutide pens which can be used multiple times, allowing patients to select and administer varying dosage strengths from a single unit—particularly useful during the titration phase when doses are gradually increased.
The pens available so far could dispense the drug only in a single dosage, meaning patients had to buy different pens for different doses. This was not just inconvenient but also expensive. A patient needing to titrate up would need to purchase multiple pens over the course of treatment.
Dr Sharvi Patel, managing director of Zydus, said: “We are not just planning to bring a critical therapy to market, we are aiming to elevate the standard of care. By introducing the new drug delivery mechanism in India, we plan to simplify the treatment. This leap in convenience will drive better long-term adherence.” And push down costs too.
The Risk of Misuse
With the popularity of GLP-1 drugs driven by celebrity endorsements when the first products were launched globally, there is a risk of misuse. A strong marketing push is already palpable, with companies reaching out to doctors and driving “awareness campaigns,” according to an industry expert.
That is why the apex drug regulator, the Central Drugs Standard Control Organisation (CDSCO), has issued an advisory warning manufacturers against advertising. “Any promotional activity carried out under the pretext of disease awareness, influencer engagement, corporate campaigns or similar activities that create brand recall or product visibility of the prescription product, shall also be treated as violations,” it said.
Local chemist stores are also internalising discipline. “We have written to all our members to ensure that they dispense the products only as per doctors’ prescription. We received complaints that in a few cases, Mounjaro was sold without one. That problem is likely to increase with many more drugs becoming available,” said Rajiv Singhal, general secretary of the All-India Chemists and Druggists Association.
Shrotriya also emphasised vigilance, saying: “We strongly discourage self-medication or any form of misuse of these medicines.”
The Safety Profile
While semaglutide has been in the market for years without such serious concerns in most, it does lead to adverse effects such as nausea, vomiting, and other gastrointestinal symptoms when people are starting out. It can also lead to serious side effects such as pancreatitis, thyroid cancer, and stomach paralysis.
“Responsible use remains key. It is important to distinguish between medical obesity management and cosmetic weight loss and ensure that the treatment is taken under appropriate medical supervision,” said Dr Gupta.
This distinction is crucial. Obesity is a medical condition with serious health consequences. Weight loss for cosmetic reasons is a personal choice. The same drug can serve both purposes, but the risk-benefit calculus differs. Medical supervision ensures that the drug is used appropriately, that side effects are monitored, and that patients understand what they are taking.
Conclusion: A New Era
The patent expiry of semaglutide marks a new era in India’s pharmaceutical landscape. For the millions of Indians living with diabetes and obesity, it means access to world-class treatment at affordable prices. For the pharmaceutical industry, it means competition, innovation, and the challenge of differentiating products in a crowded market.
But with access comes responsibility. The drugs must be used appropriately, under medical supervision, with awareness of risks and side effects. The regulator’s warning against advertising, the chemists’ commitment to prescription-only sales, and the manufacturers’ emphasis on responsible use are all part of ensuring that the benefits of this revolution are realised without causing harm.
The weight loss drug boom that swept the West is now coming to India. It will be bigger, more accessible, and more affordable. And if managed well, it will improve the health and well-being of millions.
Q&A: Unpacking the Semaglutide Patent Expiry
Q1: What is semaglutide and why is it significant?
A: Semaglutide is a drug that mimics the GLP-1 hormone, which is released in the gut after eating to stimulate insulin production, lower blood sugar, slow digestion, and reduce appetite. Originally approved for Type 2 diabetes in 2017, it gained popularity for its off-label use as a weight loss agent. A higher-dose version was approved for obesity in 2021. It has become a blockbuster drug worldwide, with innovator brands Ozempic (for diabetes) and Wegovy (for obesity) commanding premium prices.
Q2: How much will prices drop after patent expiry?
A: Generic versions are expected to be launched at a third to a fifth of the cost of innovator drugs. Current prices for innovator brands range from Rs 8,800 to Rs 16,400 per month depending on dosage and product. Generic versions are expected to cost between Rs 3,000 and Rs 4,000 per month—a reduction of 60 per cent or more. Nearly 50 brands are expected to enter the market initially, though only 3-4 major players are likely to capture significant market share.
Q3: What is the difference between innovator and generic drugs?
A: Generic drugs are identical to brand-name drugs in dosage, safety, strength, quality, and performance. They contain the same active ingredient and are held to the same standards. However, generics cost significantly less because manufacturers do not have to repeat costly clinical trials—they can rely on the safety and efficacy data already established by the innovator. Innovator drugs come with extensive clinical evidence, manufacturing processes, and delivery systems that some patients may value.
Q4: What are the risks associated with semaglutide?
A: Common side effects include nausea, vomiting, and gastrointestinal symptoms, particularly when starting treatment. More serious but rare side effects include pancreatitis, thyroid cancer, and stomach paralysis. The drug requires a prescription and should be used under medical supervision. Regulators and industry bodies are warning against misuse, self-medication, and inappropriate advertising, emphasising that the drug should be used for medical obesity management, not cosmetic weight loss.
Q5: How will the market evolve after patent expiry?
A: The market is expected to see a two-to-threefold surge in the number of patients using GLP-1 therapies as affordability improves. Innovator brands are likely to retain loyal customers who value premium quality and are willing to pay for it. Generic versions will expand the market by attracting price-sensitive patients. Companies are also innovating in drug delivery—for example, introducing multi-dose pens that allow patients to administer varying strengths from a single unit, improving convenience and reducing costs.
